Enforcement WatchEnforcement analysisGPhCOnline pharmacyWeight managementPrescribing safety

GPhC finds weaknesses in weight-loss pharmacy safeguards

A GPhC review of weight-management pharmacy inspections found weak risk assessments, incomplete patient records, and inconsistent BMI verification across online pharmacies.

What happened

The General Pharmaceutical Council published a review of inspection reports and concerns from January 2024 to December 2025. The findings are clear: too many online pharmacies are cutting corners on weight-management medicine safeguards.

Inspectors found weaknesses in risk assessments, clinical governance arrangements, patient consultation records, and processes for independently verifying weight and BMI before prescribing high-risk weight-loss medicines.

Who this affects

Online pharmacies prescribing Mounjaro, Wegovy, and other GLP-1 weight-loss medicines
Superintendent Pharmacists responsible for governance at these pharmacies
Patients using online pharmacies for weight-loss treatment — the safeguards exist to protect them

What it means

The GPhC has been clear since February 2025 that weight-management medicines are "high risk" and require independent BMI verification, not just questionnaire-based prescribing. This review shows enforcement is not theoretical — inspectors are finding gaps, and pharmacies that don't tighten up face investigation.

What to watch next

The GPhC says it will continue working with the MHRA and ASA on joint enforcement. Expect more targeted inspections and potentially the first enforcement actions against pharmacies that fail to meet the strengthened safeguards.

Source

GPhC: Weight management medicines and services review (April 2026)

Disclaimer: This article is for informational purposes only and does not constitute legal advice. Clinics and practitioners should seek independent legal advice for their specific circumstances.